You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Denufosol Trial
- Thread starter dramamama
- Start date
Actually, it opens a different channel than the cftr channel which is either defective or missing in cf. This drug actually causes the cells in the lungs to efflux fluid like a normal lung.....It dosen't correct the cftr channel....however, it opens another one that appears to do the same thing.
It is not just like hypertonic saline Amy. It does hydrate the lung in a much different way. The salt from hypertonic saline pulls water from the cell and allows secretions some moisture and the cilia to beat. This actually CREATES a new channel thereby changing the mechanism by which the lung hydrates itself.
It is TOTALLY different and much more effective.
Here is a direct quote from recent literature:
<b> Denufosol tetrasodium is a selective P2Y2 agonist designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms by activating an alternative ion channel that acts in the same way as the defective ion channel normally would in moving salt and water to the surface of the airways.
This is a critical development for CF patients and could represent an entirely new way to correct the basic defect in cells that line the airways, said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation</b>.
It is not just like hypertonic saline Amy. It does hydrate the lung in a much different way. The salt from hypertonic saline pulls water from the cell and allows secretions some moisture and the cilia to beat. This actually CREATES a new channel thereby changing the mechanism by which the lung hydrates itself.
It is TOTALLY different and much more effective.
Here is a direct quote from recent literature:
<b> Denufosol tetrasodium is a selective P2Y2 agonist designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms by activating an alternative ion channel that acts in the same way as the defective ion channel normally would in moving salt and water to the surface of the airways.
This is a critical development for CF patients and could represent an entirely new way to correct the basic defect in cells that line the airways, said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation</b>.
Actually, it opens a different channel than the cftr channel which is either defective or missing in cf. This drug actually causes the cells in the lungs to efflux fluid like a normal lung.....It dosen't correct the cftr channel....however, it opens another one that appears to do the same thing.
It is not just like hypertonic saline Amy. It does hydrate the lung in a much different way. The salt from hypertonic saline pulls water from the cell and allows secretions some moisture and the cilia to beat. This actually CREATES a new channel thereby changing the mechanism by which the lung hydrates itself.
It is TOTALLY different and much more effective.
Here is a direct quote from recent literature:
<b> Denufosol tetrasodium is a selective P2Y2 agonist designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms by activating an alternative ion channel that acts in the same way as the defective ion channel normally would in moving salt and water to the surface of the airways.
This is a critical development for CF patients and could represent an entirely new way to correct the basic defect in cells that line the airways, said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation</b>.
It is not just like hypertonic saline Amy. It does hydrate the lung in a much different way. The salt from hypertonic saline pulls water from the cell and allows secretions some moisture and the cilia to beat. This actually CREATES a new channel thereby changing the mechanism by which the lung hydrates itself.
It is TOTALLY different and much more effective.
Here is a direct quote from recent literature:
<b> Denufosol tetrasodium is a selective P2Y2 agonist designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms by activating an alternative ion channel that acts in the same way as the defective ion channel normally would in moving salt and water to the surface of the airways.
This is a critical development for CF patients and could represent an entirely new way to correct the basic defect in cells that line the airways, said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation</b>.